Share

    


In This Section

Home / News & Media / Oncology Newsfeed

Oncology Newsfeed

  • LeanTaaS Announces Transform Virtual Summit

    LeanTaaS will be hosting its Transform Hospital Operations Virtual Summit, which will feature a keynote address from Dr. Scott Gottlieb, from December 7 to 8. This event is hosted in partnership with Becker's Healthcare. 

    Health system executives, technology leaders, and industry experts will be brought together to discuss solutions for current pressing issues for health systems, such as backlog challenges, staffing shortages and burnout, as increased patient wait times. 

    Registration is free for all attendees. Go online to view the event's agenda and to register.

    Posted 12/6/2021


  • FDA Approves Rituximab + Chemotherapy for Pediatric Cancer Indications

    On December 2, 2021, the U.S. Food and Drug Administration approved rituximab in combination with chemotherapy for pediatric patients (greater than or equal to 6 months to less than 18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia. 

    Read the FDA announcement.

    Posted 12/6/2021



  • FDA Approves Pembrolizumab for IIB or IIC Melanoma Following Complete Resection

    On December 3, 2021, the U.S. Food and Drug Administration approved Keytruda® (pembrolizumab) for the adjuvant treatment of adult and pediatric (greater than or equal to 12 years of age) patients with stage IIB or IIC melanoma following complete resection. 

    Read the FDA announcement.

    Read Merck's announcement.

    Posted 12/6/2021



  • FDA Approves Daratumumab and Hyaluronidase-fihj in Combination for MM

    On November 30, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received one to three prior lines of therapy.

    Read the FDA announcement.

    Read Janssen, Inc.'s announcement.

    Posted 12/2/2021

     



  • Updates to Roundtable on CMS Innovation Center Health Equity Strategy

    The Center for Medicare & Medicaid Innovation (CMS Innovation Center) announced an update to its special roundtable discussion. This roundtable will discuss how the CMS Innovation Center can execute its strategic objective to advance health equity. 

    The roundtable is scheduled for Wednesday, December 8, 2021, from 1:30 to 3:00 PM EST. To participate, register online.

    Learn more about this roundtable and the CMS Innovation Center's objective in advancing health equity by reading its recently published white paper and visiting its website.

    Posted 11/30/2021


  • FDA Approves Pafolacianine for the Detection of Ovarian Cancer Lesions

    On November 29, 2021, the U.S. Food and Drug Administration (FDA) approved pafolacianine, an imaging drug intended to assist surgeons in identifying ovarian cancer lesions. The drug is designed to improve the ability to locate additional ovarian cancerous tissue that is normally difficult to detect during surgery.

    Read the FDA announcement.

    Read On Target Laboratories, Inc.'s announcement.

    Posted 11/20/2021


  • FDA Approves Sirolimus Protein-Bound Particles for PEComa

    On Novemeber 23, 2021, the U.S. Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

    Read Aadi Bioscience, Inc.'s announcement.

    Posted 11/23/2021



  • FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

    On November 17, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions.

    Read the FDA announcement.

    Read Merck's announcement.

    Posted 11/18/2021



  • U.S. MSTF Releases New Colorectal Cancer Screening Recommendation

    On Monday, November 15, 2021, the United States Multi-Society Task Force (MSTF) on Colorectal Cancer released updated screening recommendations. The Task Force now suggests that colorectal cancer screening starts in average-risk individuals age 45 to 49. This update is aligned with multiple other professional societies, including the United States Preventative Services Task Force, National Comprehensive Cancer Network, and American Cancer Society.

    Unchanged recommendations from their 2017 update include:

    • Strong recommendation for colorectal cancer screening in all individuals age 50 to 75 who have not already initiated screening.
    • For individuals age 75 to 85, the decision to start or continue screening should be based on prior screening history, comorbidity, life expectancy, colorectal cancer risk, and personal preference.
    • Screening is not recommended for individuals after age 85.

    The Multi-Society Task Force on Colorectal Cancer is represented by the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy.

    Full recommendations were published online via Gastrointestinal Endoscopy, Gastroenterology, and The American Journal of Gastroenterology. All articles will be available in January 2022 print issues.

    Posted 11/16/2021

     



  • FDA Approves Ropeginterferon Alfa-2b-NJFT for Polycythemia Vera

    On November 12, 2021, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.

    Read the FDA announcement.

    Read PharmaEssentia's announcement for more information.

    Posted 11/15/2021